News
-
August 21, 2023We will have a booth at BioJapan, a partnering event (Location: Pacifico Yokohama, October 11 (Wed) - 13 (Fri), 2023, 10:00-17:00). We will be located at booth area, booth number: C-12, so please stop by if you are interested in our activities.
-
July 1, 2023We have opened an official LinkdIn account for MiraBiologics, Inc. We will announce hot information about our company from time to time, so please follow us if you are interested.
-
June 27, 2023June 26: Our founding director, Professor Hiroaki Suga at the University of Tokyo, attended the 2023 Wolf Prize for Chemistry award ceremony held on June 15 and accepted the award. We congratulate him on receiving the prestigious Wolf Prize.
-
May 10, 2023May 10: We have renewed our website.
-
February 9, 2023Feb 9: Our founding director, Prof. Hiroaki Suga at the University of Tokyo, has been awarded the prestigious 2023 Wolf Prize in Chemistry.
-
December 5, 2022Feb 1 [Japanese Only] Prof. Junichi Takagi, Osaka University, and Prof. Hiroaki Suga, University of Tokyo, have contributed an article on LassoGraft Technology in "Jikken Igaku Zokan Vol. 40 No. 20, Antibody Medicine Expands Therapeutic Possibilities" published by Yodosha.
-
November 24, 2022Nov 24: A paper on Lassograft Technology by Associate Prof. Katsuya Sakai, Kanazawa University, Prof. Kunio Mastumoto, Kanazawa University, Prof. Junichi Takagi, Osaka University and Prof. Hiroaki Suga, University of Tokyo was introduced in the Nature biomedical engineering, “news & views” (Nat Biomed Eng, 24 Nov (2022). https://www.nature.com/articles/s41551-022-00974-3).
-
November 7, 2022Nov 8: A paper on Lassograft Technology by Associate Prof. Katsuya Sakai, Kanazawa University, Prof. Kunio Mastumoto, Kanazawa University, Prof. Junichi Takagi, Osaka University and Prof. Hiroaki Suga, University of Tokyo was published in the Nature biomedical engineering (Nat Biomed Eng, 07 Nov (2022). https://doi.org/10.1038/s41551-022-00955-6).
-
August 10, 2021Aug 10: Our Company entered into a drug discovery collaboration agreement with Ono Pharmaceutical Co., Ltd. (TSE First Section: Securities Code 4528) to create next-generation biopharmaceuticals using our proprietary LassoGraft Technology that integrates cyclic peptide discovery method (RaPID System) with protein engineering (PDF attached).
-
March 10, 2021Mar 9: A paper on Lassograft Technology by Prof. Junichi Takagi, Osaka University, and Prof. Hiroaki Suga, University of Tokyo was published in the Nature Communications (Nature Commun 12, 1543 (2021). https://doi.org/10.1038/s41467-021-21875-0).
-
June 29, 2020Jun 29: Our company has been selected for NEDO’s (New Energy and Industrial Technology Development Organization) FY2020 “Research and Development Venture Support Program / Commercialization Support for Research and Development Ventures at Seed Stage”. The title of the grant is “Verification of the Pharmaceutical Properties of Met Agonists for the Treatment of NASH” and we will promote our own development project.
-
January 17, 2020Feb 8 [Japanese Only] President Kato appeared at BS Fuji “konokuninoyukusue2 (every Saturday from 18:00 to 18:30)”, introduced our business (Part 2).
-
January 17, 2020Feb 1 [Japanese Only] President Kato appeared at BS Fuji “konokuninoyukusue2 (every Saturday from 18:00 to 18:30)”, introduced our business (Part 1).